Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer

HIGHLIGHTS

• who: Carlos H. Barrios from the (UNIVERSITY) have published the research work: Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer, in the Journal: (JOURNAL) of 15/Nov/2021
• what: The randomized, double-blind, phase III IMpassion031 study aimed to improve outcomes by adding the programmed deathligand 1 (PD-L1)-targeted checkpoint inhibitor atezolizumab to a neoadjuvant regimen of nab-paclitaxel followed by dose-dense doxorubicin plus cyclophosphamide6. The authors report results for prespecified PRO endpoints in the IMpassion031 study, investigating the impact of the addition of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.